CADL Stock Overview
A clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Candel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.01 |
| 52 Week High | US$14.30 |
| 52 Week Low | US$0.66 |
| Beta | -0.93 |
| 11 Month Change | 33.27% |
| 3 Month Change | -3.84% |
| 1 Year Change | 456.35% |
| 33 Year Change | -10.59% |
| 5 Year Change | n/a |
| Change since IPO | 0.14% |
Recent News & Updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Recent updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Shareholder Returns
| CADL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 14.2% | 5.6% | 4.2% |
| 1Y | 456.3% | 19.5% | 24.4% |
Return vs Industry: CADL exceeded the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: CADL exceeded the US Market which returned 22% over the past year.
Price Volatility
| CADL volatility | |
|---|---|
| CADL Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CADL's share price has been volatile over the past 3 months.
Volatility Over Time: CADL's weekly volatility has decreased from 43% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 42 | Paul-Peter Tak | www.candeltx.com |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma.
Candel Therapeutics, Inc. Fundamentals Summary
| CADL fundamental statistics | |
|---|---|
| Market cap | US$210.80m |
| Earnings (TTM) | -US$49.99m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs CADL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CADL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$21.66m |
| Gross Profit | -US$21.66m |
| Other Expenses | US$28.33m |
| Earnings | -US$49.99m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -173.7% |
How did CADL perform over the long term?
See historical performance and comparison